難治性急性骨髄性白血病(Refractory Acute Myeloid Leukemia):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2014
◆商品コード:GMDHC5697IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:302
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における難治性急性骨髄性白血病(Refractory Acute Myeloid Leukemia)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・難治性急性骨髄性白血病(Refractory Acute Myeloid Leukemia)の概要
・難治性急性骨髄性白血病(Refractory Acute Myeloid Leukemia)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・難治性急性骨髄性白血病(Refractory Acute Myeloid Leukemia)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・難治性急性骨髄性白血病(Refractory Acute Myeloid Leukemia)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・難治性急性骨髄性白血病(Refractory Acute Myeloid Leukemia)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Refractory Acute Myeloid Leukemia – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Refractory Acute Myeloid Leukemia – Pipeline Review, H2 2014’, provides an overview of the Refractory Acute Myeloid Leukemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Refractory Acute Myeloid Leukemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Refractory Acute Myeloid Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Refractory Acute Myeloid Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Refractory Acute Myeloid Leukemia Overview 9
Therapeutics Development 10
Pipeline Products for Refractory Acute Myeloid Leukemia – Overview 10
Pipeline Products for Refractory Acute Myeloid Leukemia – Comparative Analysis 11
Refractory Acute Myeloid Leukemia – Therapeutics under Development by Companies 12
Refractory Acute Myeloid Leukemia – Therapeutics under Investigation by Universities/Institutes 17
Refractory Acute Myeloid Leukemia – Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Refractory Acute Myeloid Leukemia – Products under Development by Companies 21
Refractory Acute Myeloid Leukemia – Products under Investigation by Universities/Institutes 25
Refractory Acute Myeloid Leukemia – Companies Involved in Therapeutics Development 26
AbbVie Inc. 26
Actinium Pharmaceuticals, Inc. 27
Agios Pharmaceuticals, Inc. 28
Altor BioScience Corporation 29
Ambit Biosciences Corporation 30
Amgen Inc. 31
Astellas Pharma Inc. 32
Astex Pharmaceuticals, Inc. 33
AstraZeneca PLC 34
AVEO Pharmaceuticals, Inc. 35
Boehringer Ingelheim GmbH 36
Bristol-Myers Squibb Company 37
Celgene Corporation 38
Conkwest, Inc. 39
Cornerstone Pharmaceuticals, Inc. 40
CTI BioPharma Corp. 41
Eisai Co., Ltd. 42
EpiZyme, Inc. 43
Exelixis, Inc. 44
F. Hoffmann-La Roche Ltd. 45
Fujifilm Corporation 46
GlaxoSmithKline plc 47
Igenica Biotherapeutics, Inc. 48
Incyte Corporation 49
Jiangsu Hansoh Pharmaceutical Co., Ltd. 50
JW Pharmaceutical Corporation 51
Karyopharm Therapeutics, Inc. 52
Kyowa Hakko Kirin Co., Ltd. 53
Les Laboratoires Servier SAS 54
MacroGenics, Inc. 55
Merck & Co., Inc. 56
Millennium Pharmaceuticals, Inc. 57
Novartis AG 58
Piramal Enterprises Limited 59
Plexxikon Inc. 60
Polaris Group 61
Seattle Genetics, Inc. 62
SpectraMab GmbH 63
Sunesis Pharmaceuticals, Inc. 64
Synta Pharmaceuticals Corp. 65
Targa Therapeutics Corp. 66
Tolero Pharmaceuticals, Inc. 67
Verastem, Inc. 68
Refractory Acute Myeloid Leukemia – Therapeutics Assessment 69
Assessment by Monotherapy Products 69
Assessment by Target 70
Assessment by Mechanism of Action 75
Assessment by Route of Administration 78
Assessment by Molecule Type 80
Drug Profiles 82
AG-120 – Drug Profile 82
AG-221 – Drug Profile 84
ALT-801 – Drug Profile 87
alvocidib hydrochloride – Drug Profile 89
AMG-232 – Drug Profile 90
AT-9283 – Drug Profile 91
BI-836858 – Drug Profile 93
binimetinib – Drug Profile 94
bortezomib – Drug Profile 98
brentuximab vedotin – Drug Profile 103
cabozantinib s-malate – Drug Profile 108
cafusertib hydrochloride – Drug Profile 111
Cell Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia – Drug Profile 112
Cell Therapy to Target CD33 for Acute Myeloid Leukemia – Drug Profile 113
Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies – Drug Profile 114
CPI-613 – Drug Profile 115
crenolanib besylate – Drug Profile 117
CST-101 – Drug Profile 119
CWP-291 – Drug Profile 121
DFP-10917 – Drug Profile 123
elesclomol – Drug Profile 124
EPZ-5676 – Drug Profile 126
erlotinib hydrochloride – Drug Profile 127
FF-10501 – Drug Profile 130
ficlatuzumab – Drug Profile 131
gilteritinib – Drug Profile 133
GSK-2879552 – Drug Profile 134
GSK-525762 – Drug Profile 135
HuM-195/rGel – Drug Profile 136
IGN-523 – Drug Profile 137
ilorasertib – Drug Profile 138
imatinib mesylate – Drug Profile 140
indisulam – Drug Profile 142
Iomab-B – Drug Profile 143
KHK-2823 – Drug Profile 145
LGH-447 – Drug Profile 146
MGD-006 – Drug Profile 147
midostaurin – Drug Profile 148
MK-2206 – Drug Profile 150
P-2745 – Drug Profile 153
PD-616 – Drug Profile 154
pegargiminase – Drug Profile 156
PLX-3397 – Drug Profile 159
quizartinib – Drug Profile 161
RG-7775 – Drug Profile 163
ruxolitinib phosphate – Drug Profile 164
S-055746 – Drug Profile 168
selinexor – Drug Profile 169
selumetinib sulfate – Drug Profile 172
Small Molecules to Inhibit MDM2 for Oncology – Drug Profile 175
temozolomide – Drug Profile 176
tigecycline – Drug Profile 178
tosedostat – Drug Profile 179
trametinib dimethyl sulfoxide + uprosertib – Drug Profile 181
Triplebody 19x16x19 – Drug Profile 183
ulocuplumab – Drug Profile 184
venetoclax – Drug Profile 185
vorinostat – Drug Profile 188
vosaroxin – Drug Profile 192
VS-4718 – Drug Profile 194
ZEN-3365 – Drug Profile 195
Refractory Acute Myeloid Leukemia – Recent Pipeline Updates 196
Refractory Acute Myeloid Leukemia – Dormant Projects 284
Refractory Acute Myeloid Leukemia – Discontinued Products 285
Refractory Acute Myeloid Leukemia – Product Development Milestones 286
Featured News & Press Releases 286
Appendix 297
Methodology 297
Coverage 297
Secondary Research 297
Primary Research 297
Expert Panel Validation 297
Contact Us 298
Disclaimer 298

[List of Tables]
Number of Products under Development for Refractory Acute Myeloid Leukemia, H2 2014 14
Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 17
Number of Products under Development by Companies, H2 2014 (Contd..1) 18
Number of Products under Development by Companies, H2 2014 (Contd..2) 19
Number of Products under Development by Companies, H2 2014 (Contd..3) 20
Number of Products under Investigation by Universities/Institutes, H2 2014 21
Comparative Analysis by Late Stage Development, H2 2014 22
Comparative Analysis by Clinical Stage Development, H2 2014 23
Comparative Analysis by Early Stage Development, H2 2014 24
Products under Development by Companies, H2 2014 25
Products under Development by Companies, H2 2014 (Contd..1) 26
Products under Development by Companies, H2 2014 (Contd..2) 27
Products under Development by Companies, H2 2014 (Contd..3) 28
Products under Investigation by Universities/Institutes, H2 2014 29
Refractory Acute Myeloid Leukemia - Pipeline by AbbVie Inc., H2 2014 30
Refractory Acute Myeloid Leukemia - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 31
Refractory Acute Myeloid Leukemia - Pipeline by Agios Pharmaceuticals, Inc., H2 2014 32
Refractory Acute Myeloid Leukemia - Pipeline by Altor BioScience Corporation, H2 2014 33
Refractory Acute Myeloid Leukemia - Pipeline by Ambit Biosciences Corporation, H2 2014 34
Refractory Acute Myeloid Leukemia - Pipeline by Amgen Inc., H2 2014 35
Refractory Acute Myeloid Leukemia - Pipeline by Astellas Pharma Inc., H2 2014 36
Refractory Acute Myeloid Leukemia - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 37
Refractory Acute Myeloid Leukemia - Pipeline by AstraZeneca PLC, H2 2014 38
Refractory Acute Myeloid Leukemia - Pipeline by AVEO Pharmaceuticals, Inc., H2 2014 39
Refractory Acute Myeloid Leukemia - Pipeline by Boehringer Ingelheim GmbH, H2 2014 40
Refractory Acute Myeloid Leukemia - Pipeline by Bristol-Myers Squibb Company, H2 2014 41
Refractory Acute Myeloid Leukemia - Pipeline by Celgene Corporation, H2 2014 42
Refractory Acute Myeloid Leukemia - Pipeline by Conkwest, Inc., H2 2014 43
Refractory Acute Myeloid Leukemia - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2014 44
Refractory Acute Myeloid Leukemia - Pipeline by CTI BioPharma Corp., H2 2014 45
Refractory Acute Myeloid Leukemia - Pipeline by Eisai Co., Ltd., H2 2014 46
Refractory Acute Myeloid Leukemia - Pipeline by EpiZyme, Inc., H2 2014 47
Refractory Acute Myeloid Leukemia - Pipeline by Exelixis, Inc., H2 2014 48
Refractory Acute Myeloid Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 49
Refractory Acute Myeloid Leukemia - Pipeline by Fujifilm Corporation, H2 2014 50
Refractory Acute Myeloid Leukemia - Pipeline by GlaxoSmithKline plc, H2 2014 51
Refractory Acute Myeloid Leukemia - Pipeline by Igenica Biotherapeutics, Inc., H2 2014 52
Refractory Acute Myeloid Leukemia - Pipeline by Incyte Corporation, H2 2014 53
Refractory Acute Myeloid Leukemia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2014 54
Refractory Acute Myeloid Leukemia - Pipeline by JW Pharmaceutical Corporation, H2 2014 55
Refractory Acute Myeloid Leukemia - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 56
Refractory Acute Myeloid Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 57
Refractory Acute Myeloid Leukemia - Pipeline by Les Laboratoires Servier SAS, H2 2014 58
Refractory Acute Myeloid Leukemia - Pipeline by MacroGenics, Inc., H2 2014 59
Refractory Acute Myeloid Leukemia - Pipeline by Merck & Co., Inc., H2 2014 60
Refractory Acute Myeloid Leukemia - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 61
Refractory Acute Myeloid Leukemia - Pipeline by Novartis AG, H2 2014 62
Refractory Acute Myeloid Leukemia - Pipeline by Piramal Enterprises Limited, H2 2014 63
Refractory Acute Myeloid Leukemia - Pipeline by Plexxikon Inc., H2 2014 64
Refractory Acute Myeloid Leukemia - Pipeline by Polaris Group, H2 2014 65
Refractory Acute Myeloid Leukemia - Pipeline by Seattle Genetics, Inc., H2 2014 66
Refractory Acute Myeloid Leukemia - Pipeline by SpectraMab GmbH, H2 2014 67
Refractory Acute Myeloid Leukemia - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2014 68
Refractory Acute Myeloid Leukemia - Pipeline by Synta Pharmaceuticals Corp., H2 2014 69
Refractory Acute Myeloid Leukemia - Pipeline by Targa Therapeutics Corp., H2 2014 70
Refractory Acute Myeloid Leukemia - Pipeline by Tolero Pharmaceuticals, Inc., H2 2014 71
Refractory Acute Myeloid Leukemia - Pipeline by Verastem, Inc., H2 2014 72
Assessment by Monotherapy Products, H2 2014 73
Number of Products by Stage and Target, H2 2014 76
Number of Products by Stage and Mechanism of Action, H2 2014 80
Number of Products by Stage and Route of Administration, H2 2014 83
Number of Products by Stage and Molecule Type, H2 2014 85
Refractory Acute Myeloid Leukemia Therapeutics - Recent Pipeline Updates, H2 2014 200
Refractory Acute Myeloid Leukemia - Dormant Projects, H2 2014 288
Refractory Acute Myeloid Leukemia - Discontinued Products, H2 2014 289

[List of Figures]
Number of Products under Development for Refractory Acute Myeloid Leukemia, H2 2014 14
Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 16
Number of Products under Investigation by Universities/Institutes, H2 2014 21
Comparative Analysis by Clinical Stage Development, H2 2014 23
Comparative Analysis by Early Stage Products, H2 2014 24
Assessment by Monotherapy Products, H2 2014 73
Number of Products by Top 10 Targets, H2 2014 74
Number of Products by Stage and Top 10 Targets, H2 2014 75
Number of Products by Top 10 Mechanism of Actions, H2 2014 79
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 79
Number of Products by Top 10 Routes of Administration, H2 2014 82
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 83
Number of Products by Top 10 Molecule Types, H2 2014 84
Number of Products by Stage and Top 10 Molecule Types, H2 2014 85

【掲載企業】

AbbVie Inc.
Actinium Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Altor BioScience Corporation
Ambit Biosciences Corporation
Amgen Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca PLC
AVEO Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Conkwest, Inc.
Cornerstone Pharmaceuticals, Inc.
CTI BioPharma Corp.
Eisai Co., Ltd.
EpiZyme, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Fujifilm Corporation
GlaxoSmithKline plc
Igenica Biotherapeutics, Inc.
Incyte Corporation
Jiangsu Hansoh Pharmaceutical Co., Ltd.
JW Pharmaceutical Corporation
Karyopharm Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Les Laboratoires Servier SAS
MacroGenics, Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Piramal Enterprises Limited
Plexxikon Inc.
Polaris Group
Seattle Genetics, Inc.
SpectraMab GmbH
Sunesis Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Targa Therapeutics Corp.
Tolero Pharmaceuticals, Inc.
Verastem, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[難治性急性骨髄性白血病(Refractory Acute Myeloid Leukemia):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆